Data Sheet (Cat.No.TMAB-03884)

TargetMol

Anti-CD19 Polyclonal Antibody 2

Product Details

Ig Type:	IgG
Reactivity:	Human
Molecular Weight:	Theoretical: 59 kDa.
Purification:	Protein A purified

Applications

Verified Activity:	Blank control (blue line): HL60 cells (fixed with 70% methanol (Overnight at 4℃). Cells stained with Primary Antibody for 30 min at room temperature). Primary Antibody (green line): Rabbit Anti-CD19 antibody (TMAB-03884), Dilution: 0.2 µg /10^6 cells; Isotype Control Antibody (orange line): Rabbit IgG. Secondary Antibody (white blue line): Goat anti-rabbit IgG-PE, Dilution: 1 µg /test.
Application:	FCM
Recommended	FCM: 1µg/Test

Properties

Stability & Storage:	Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles.
Shipping:	Shipping with blue ice.

Antigen Details

Immunogen:	KLH conjugated synthetic peptide: human CD19
Antigen Species:	Human
Gene ID:	930
Uniprot ID:	P15391

Research Background

This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481